This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
ELISA/assay
product name :
Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit
catalog :
DB7H10
quantity :
1 Kit
price :
655 USD
citations: 21
Reference
Yuan Q, Fan Z, Huang W, Huo X, Yang X, Ran Y, et al. Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity. MBio. 2024;15:e0119124 pubmed publisher
Eslami S Z, Cort xe9 s Hern xe1 ndez L, Sinoquet L, Gauthier L, Vautrot V, Cayrefourcq L, et al. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br J Cancer. 2024;130:63-72 pubmed publisher
Kir xe1 ly Z, Nagy E, Bokor L, Kov xe1 cs A, Marschalk xf3 M, Hidv xe9 gi B. The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus-A Pilot Study. J Clin Med. 2023;12: pubmed publisher
Zhang L, Li H, Liu J, Sun G, Tang X, Xu S, et al. The screening of compounds regulating PD-L1 transcriptional activity in a cell functional high-throughput manner. Cancer Med. 2023;12:9815-9825 pubmed publisher
Ma J, Zhou Q, Xu W, Li C, Wang H, Zhai Z, et al. Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. Int Immunopharmacol. 2023;114:109535 pubmed publisher
Sz xe9 les x, Kov xe1 cs P, Csizmarik A, V xe1 radi M, Riesz P, Fazekas T, et al. High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma. Biomedicines. 2022;10: pubmed publisher
Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher
Chávez Galán L, Ruiz A, Martinez Espinosa K, Aguilar Duran H, Torres M, Falfan Valencia R, et al. Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation. Biomolecules. 2022;12: pubmed publisher
Nakano K, Yokoyama K, Shin S, Uchida K, Tsuji K, Tanaka M, et al. Exploring New Functional Aspects of HTLV-1 RNA-Binding Protein Rex: How Does Rex Control Viral Replication?. Viruses. 2022;14: pubmed publisher
Vikerfors A, Davidsson S, Frey J, Jerlström T, Carlsson J. Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. Cancers (Basel). 2021;13: pubmed publisher
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al. Protein detection in blood with single-molecule imaging. Sci Adv. 2021;7: pubmed publisher
Tosev G, Wahafu W, Reimold P, Damgov I, Schwab C, Aksoy C, et al. Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Sci Rep. 2021;11:14244 pubmed publisher
Mocan T, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94:107467 pubmed publisher
Xu J, Wang J, Wang X, Tan R, Qi X, Liu Z, et al. Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages. Cell Death Dis. 2020;11:934 pubmed publisher
Fei Y, Yu J, Li Y, Li L, Zhou S, Zhang T, et al. Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. J Cancer. 2020;11:7001-7008 pubmed publisher
Cui L, Chen S, Lerbs T, Lee J, Domizi P, Gordon S, et al. Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nat Commun. 2020;11:2795 pubmed publisher
Castello A, Rossi S, Toschi L, Mansi L, Lopci E. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. Cancers (Basel). 2020;12: pubmed publisher
Chiarucci C, Cannito S, Daffinà M, Amato G, Giacobini G, Cutaia O, et al. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel). 2020;12: pubmed publisher
Yang J, Hu G. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett. 2019;17:3382-3386 pubmed publisher
Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res. 2018;19:197 pubmed publisher
Kim H, Park S, Kim K, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol. 2018;129:130-135 pubmed publisher
product information
master code :
DB7H10
SKU :
DB7H10
product name :
Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit
unit size :
1 Kit
description :
The Human/Cynomolgus Monkey PD-L1/B7-H1 Quantikine ELISA Kit from R&D Systems quantifies human, cynomolgus monkey PD-L1 in cell culture supernates (100 ul), cell lysates (100 ul), serum (100 ul), edta plasma (100 ul), heparin plasma (100 ul), urine (100 ul).
target :
PD-L1/B7-H1
category :
ELISAs
species :
Human, Cynomolgus Monkey
specificity :
Natural and recombinant human B7-H1/PD-L1. This assay also recognizes natural cynomolgus monkey B7-H1/PD-L1.
assay length :
4.5 hours
elisaSampleTypes :
Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (100 uL), EDTA Plasma (100 uL), Heparin Plasma (100 uL), Urine (100 uL)
elisaSensitivity :
4.52 pg/mL
elisaRange :
25.00 - 1600 pg/mL
top caption :
Human PD-L1/B7-H1 ELISA Cell Culture Supernate/Cell Lysate/Serum/Plasma Standard Curve
applications :
ELISA
USD :
655 USD
product details :
The Quantikine« Human/Cynomolgus Monkey B7-H1/PD-L1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human/cynomolgus monkey B7-H1 in cell culture supernates, cell lysates, serum, plasma, and urine. It contains HEK293-expressed recombinant human B7-H1/PD-L1 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human/cynomolgus monkey B7-H1/PD-L1 showed linear curves that were parallel to the standard curves obtained using the Quantikine« kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human/cynomolgus monkey B7-H1/PD-L1. Read this White Paper on detecting B7-H1/PD-L1 levels in multiple cancer subtypes.
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.